Medical expert of the article
New publications
Preparations
Tarivid
Last reviewed: 03.07.2025
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
An antimicrobial drug from the fluoroquinolone group, Tarivid, is a derivative of naphthidrine, with the active ingredient ofloxacin.
Indications Tarivida
The antibacterial agent Tarivid is used to treat patients with infectious diseases caused by microorganisms that are sensitive to the action of ofloxacin.
It is appropriate to use Tarivid for the following diseases:
- various forms of infectious pathologies of the respiratory organs, including inflammation of the lungs and bronchi caused by the bacterium Haemophilus influenzae, as well as pathogens such as Escherichia coli, Proteus, Enterobacter, Staphylococcus aureus, Legionella, Klebsiella;
- various forms of otolaryngological pathologies caused by staphylococcal and pseudomonas flora (exception: tonsillar angina);
- infectious pathologies of the skin and musculoskeletal system caused by sensitive flora;
- abdominal infectious pathologies.
The use of Tarivid is permitted to prevent the development of infectious complications in individuals with weakened immunity (for example, with neutropenia).
Given the range of antimicrobial activity, it is not recommended to prescribe Tarivid for pathologies caused by pneumococci and β-hemolytic streptococci.
[ 1 ]
Release form
The antibiotic Tarivid is a film-coated tablet with the main ingredient ofloxacin.
The tablets are white-yellowish in color, elongated, convex on both sides, with a dosing line and the inscription M on one side surface and XI on the other.
The drug is packaged with 10 tablets in a cellular package. The overall package is made of cardboard.
[ 2 ]
Pharmacodynamics
The bactericidal agent Tarivid contains ofloxacin, an antibacterial ingredient belonging to the second generation of fluoroquinolone drugs.
Tarivid has a broad spectrum of antimicrobial activity: the drug's action is due to the inhibition of DNA gyrase with subsequent disruption of microbial DNA replication.
Tarivid acts on strains of Staphylococcus aureus (also on methicillin-resistant variants), Neucheria, Citrobacter, Enterobacter, Escherichia, Klebsiella, Naphnia, Campylobacter, Chlamydia, Shigella, Proteus, etc.
There are strains recognized as moderately sensitive to the drug Tarivid. These include, among others, tuberculosis mycobacteria.
There is no sensitivity to Tarivid in such microorganisms as strains of nocardia, ureaplasma, and anaerobic bacteria. Tarivid is ineffective against pale treponema.
Pharmacokinetics
Tarivid is almost completely absorbed in the digestive system. The maximum content in plasma is detected an hour after taking the medication.
Bioavailability is equal to 100%.
Plasma albumin binding is 25%.
A single dose of Tarivid results in a maximum concentration of 2.5 to 3 mg/ml. The distribution volume is 120 l.
Plasma levels do not change during Tarivid therapy. The half-life can be between six and seven hours.
Approximately 5% of the consumed amount of Tarivid undergoes metabolic changes. About 90% leaves the body unchanged.
Dosing and administration
Tarivid is usually taken orally, at regular intervals. The drug can be taken with food or before meals.
The required amount of Tarivid is determined taking into account the severity of the infectious pathology, kidney function, microbial resistance and the general health of the person.
For patients with normal renal function, treatment with 200 mg of Tarivid is recommended at 12-hour intervals. The average daily dose of the drug is 400 mg. If necessary, 400 mg per day can be taken in one dose (preferably shortly before bedtime).
In cases where the patient is prescribed a daily amount of the drug exceeding 400 mg, it must be taken in two doses.
If the patient has a severe infectious pathology or is severely obese, then it is possible to increase the daily amount of Tarivid (600 mg and above).
The maximum daily dose of the drug is 800 mg.
If the patient has renal dysfunction, dosage adjustment may be required:
- if creatinine clearance is less than 50 ml per minute, then treatment with 100-200 mg Tarivid once a day is appropriate;
- If creatinine clearance is less than 20 ml per minute, treatment with 100 mg Tarivid once a day is appropriate (alternatively, 200 mg Tarivid once every two days, at the same time).
In case of insufficient liver function, it is contraindicated to consume more than 400 mg of Tarivid daily.
As a rule, the therapeutic course continues until the clinical symptoms of the infectious lesion are eliminated + 2-3 days.
During the entire course of treatment, it is recommended to avoid exposure to ultraviolet rays.
Use Tarivida during pregnancy
The antibiotic Tarivid cannot be prescribed for the treatment of women during pregnancy.
If the patient is breastfeeding, then treatment with Tarivid during the entire lactation period is also contraindicated.
Contraindications
Tarivid therapy should not be used:
- in case of hypersensitivity to drugs of the fluoroquinolone group;
- in case of lactose intolerance;
- in epilepsy;
- in the presence of complications caused by earlier use of fluoroquinolones.
Tarivid is not used to treat children under 18 years of age, as well as pregnant and lactating patients.
Relative contraindications are:
- vascular atherosclerotic changes;
- impaired cerebral circulation;
- chronic renal failure;
- organic pathologies of the central nervous system;
- prolonged QT interval.
Side effects Tarivida
During the course of taking Tarivid, various undesirable effects may occur:
- pain in the stomach and throughout the abdomen;
- defecation disorders;
- nausea, loss of appetite;
- inflammatory processes in the intestines;
- sleep disorders, overexcitement;
- headaches, dizziness, hallucinations;
- anxiety, worry;
- depression, impaired motor function, convulsions;
- extrapyramidal disorders;
- increased heart rate, hypotension;
- joint pain, tendinitis, muscle pain, myasthenia gravis;
- cholestatic jaundice, hepatitis;
- exacerbation of renal failure or nephritis;
- thrombocytopenia, agranulocytosis, anemia;
- deterioration of hematopoietic function.
An allergic reaction can be expressed by itching, rashes, conjunctivitis, allergic rhinitis.
If the patient suffers from diabetes, then the use of Tarivid may cause hypoglycemia.
If side effects are detected during therapy with Tarivid, it is imperative to inform the doctor about this, since individual undesirable symptoms may be a reason for immediate discontinuation of the drug.
[ 13 ]
Overdose
Taking high doses of Tarivid may cause dizziness, depression of consciousness, disorientation, drowsiness, and vomiting.
If there is a suspicion of an overdose of Tarivid, it is necessary to wash the stomach as soon as possible, take a sorbent drug. If necessary, treatment is prescribed depending on the pathological symptoms detected.
No special drugs with antidote properties have been found.
Interactions with other drugs
Antacids containing aluminum, magnesium, zinc or iron impair the absorption of Tarivid. If taking such drugs is unavoidable, it is important to maintain a 2-hour interval between taking Tarivid and taking antacids.
If concomitant treatment with vitamin K antagonists is carried out, the quality of blood clotting should be regularly monitored.
An increase in the level of ofloxacin may be observed during concomitant treatment with Tarivid with methotrexate, furosemide, cimetidine.
It is not advisable to take Tarivid in combination with non-steroidal anti-inflammatory drugs and theophylline, as this may increase the likelihood of developing seizures.
A neurotoxic effect may be observed after taking Tarivid in combination with non-steroidal anti-inflammatory drugs and nitroimidazole-based drugs.
Tarivid should not be combined with glucocorticosteroids, as this increases the risk of tendon damage.
Due to the risk of prolongation of the QT interval, Tarivid should not be combined with antiarrhythmic drugs, macrolide antibiotics, or antidepressants.
Due to the risk of kidney damage, it is undesirable to combine Tarivid with citrates, carbonic anhydrase inhibitors, and sodium bicarbonate.
Storage conditions
Antibiotic storage areas should be away from direct sunlight and dampness. Children should not have access to such storage areas for medications, including Tarivid.
There is no need to maintain a special temperature regime.
Attention!
To simplify the perception of information, this instruction for use of the drug "Tarivid" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.